These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10696294)

  • 21. Effect of omeprazole on gastric acid secretion in man.
    Olbe L; Lind T; Cederberg C; Ekenved G
    Scand J Gastroenterol Suppl; 1986; 118():105-7. PubMed ID: 3460164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients.
    Thomson AB; Keelan M; Lastiwka R; Appelman-Eszczuk S; Zuk L; Drozdowski L; Prentice A; Sinclair P
    Dig Dis Sci; 2003 Oct; 48(10):2045-56. PubMed ID: 14627354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole.
    Andersson T; Röhss K; Bredberg E; Hassan-Alin M
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1563-9. PubMed ID: 11563995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.
    Pratha VS; Hogan DL; Lane JR; Williams PJ; Burton MS; Lynn RB; Karlstadt RG
    Dig Dis Sci; 2006 Jan; 51(1):123-31. PubMed ID: 16416224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
    Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
    Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of single intravenously administered doses of omeprazole and ranitidine on intragastric pH and plasma gastrin concentration in nonfed ponies.
    Baker SJ; Gerring EL
    Am J Vet Res; 1993 Dec; 54(12):2068-74. PubMed ID: 8116940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring.
    Takeda H; Hokari K; Asaka M
    J Clin Gastroenterol; 1995; 20 Suppl 1():S7-9. PubMed ID: 7673616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of omeprazole paste on intragastric pH in clinically normal neonatal foals.
    Sanchez LC; Murray MJ; Merritt AM
    Am J Vet Res; 2004 Aug; 65(8):1039-41. PubMed ID: 15334835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of omeprazole on the pharmacokinetics of metronidazole and hydroxymetronidazole in human plasma, saliva and gastric juice.
    Jessa MJ; Goddard AF; Barrett DA; Shaw PN; Spiller RC
    Br J Clin Pharmacol; 1997 Sep; 44(3):245-53. PubMed ID: 9296318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Noninvasive assessment of gastric acid secretion in man. Application of electrical impedance tomography (EIT).
    Sarker SA; Mahalanabis D; Bardhan PK; Alam NH; Rabbani KS; Kiber A; Hassan M; Islam S; Fuchs GJ; Gyr K
    Dig Dis Sci; 1997 Aug; 42(8):1804-9. PubMed ID: 9286252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preliminary investigations into a novel, long-acting, injectable, intramuscular formulation of omeprazole in the horse.
    Sykes BW; Kathawala K; Song Y; Garg S; Page SW; Underwood C; Mills PC
    Equine Vet J; 2017 Nov; 49(6):795-801. PubMed ID: 28397996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole.
    Gillen D; Wirz AA; Neithercut WD; Ardill JE; McColl KE
    Gut; 1999 Apr; 44(4):468-75. PubMed ID: 10075952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
    Katz PO; Hatlebakk JG; Castell DO
    Aliment Pharmacol Ther; 2000 Jun; 14(6):709-14. PubMed ID: 10848653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioavailability and efficacy of omeprazole given orally and by nasogastric tube.
    Larson C; Cavuto NJ; Flockhart DA; Weinberg RB
    Dig Dis Sci; 1996 Mar; 41(3):475-9. PubMed ID: 8617118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of omeprazole on gastric juice viscosity, pH and bacterial counts.
    Goddard AF; Spiller RC
    Aliment Pharmacol Ther; 1996 Feb; 10(1):105-9. PubMed ID: 8871450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Animal pharmacodynamics of omeprazole. A survey of its pharmacological properties in vivo.
    Larsson H; Mattson H; Sundell G; Carlsson E
    Scand J Gastroenterol Suppl; 1985; 108():23-35. PubMed ID: 3858975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease?
    Hendel J; Hendel L; Aggestrup S
    Aliment Pharmacol Ther; 1995 Dec; 9(6):693-7. PubMed ID: 8824658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circadian differences in pharmacological blockade of meal-stimulated gastric acid secretion.
    Sanders SW; Moore JG; Day GM; Tolman KG
    Aliment Pharmacol Ther; 1992 Apr; 6(2):187-93. PubMed ID: 1600040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.